# Erasca Inc. (ERAS) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $16.19, market value $5.7 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Erasca Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 14.0×**. The shares trade at 14.0× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -1.7%** (5-yr avg -18.2%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -38.3%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): 36.2%**. Earnings per share rose 36.2%.

## Financial health
- **Current ratio: 10.04** (quick 10.04). Current assets cover the next year's liabilities 10.04 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Erasca Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (10 analysts). 10 analysts cover Erasca Inc.; the consensus is buy, with an average price target of $24.30 (+50% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 993.9%** (YTD 335.2%, 3-mo 35.3%). The shares are up 993.9% over twelve months including dividends.
- **From 52-week high: -33.3%** (961.6% above the low). Trading 33% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 38**. An RSI of 38 is neutral.
- **Beta (1 yr): 1.08** (volatility 104%). Beta of 1.08 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ERAS · Page: https://foliofundamentals.com/stocks/eras

Not investment advice.